#156471

Anti-phospho Pax3 [Ser201]

Cat. #156471

Anti-phospho Pax3 [Ser201]

Cat. #: 156471

Sub-type: Primary antibody

Unit size: 100 ug

Target: Phosphorylated Ser201 of Pax3

Class: Monoclonal

Application: WB

Reactivity: Human ; Mouse

Host: Rat

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Out of stock

Contributor

Inventor: Andrew Hollenbach

Institute: Louisiana University Health Sciences Center New Orleans (LSU)

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-phospho Pax3 [Ser201]
  • Research fields: Developmental biology
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Reactivity: Human ; Mouse
  • Host: Rat
  • Application: WB
  • Description: Pax3 is a transcription factor important for myogenesis and when dysregulated can cause pediatric solid muscle tumor alveolar rhabdomyosarcoma (ARMS). ARMS is primarily characterized by the t(2;13)(p35;p14) chromosomal translocation, which results in the oncogenic fusion protein Pax3-FOXO1. Using these phospho-specific antibodies it was demonstrated that the pattern of Pax3 phosphorylation at serines 201, 205, and 209 changes throughout early myogenic differentiation and that this pattern is different for Pax3-FOXO1 in primary myoblasts and in several ARMS cell lines.
  • Immunogen: synthetic peptide: NH2-CSERASAPQ(pS)DEG-CO2
  • Recommended controls: IgG

Target Details

  • Target: Phosphorylated Ser201 of Pax3
  • Tissue cell line specificity: IgG
  • Target background: Pax3 is a transcription factor important for myogenesis and when dysregulated can cause pediatric solid muscle tumor alveolar rhabdomyosarcoma (ARMS). ARMS is primarily characterized by the t(2;13)(p35;p14) chromosomal translocation, which results in the oncogenic fusion protein Pax3-FOXO1. Using these phospho-specific antibodies it was demonstrated that the pattern of Pax3 phosphorylation at serines 201, 205, and 209 changes throughout early myogenic differentiation and that this pattern is different for Pax3-FOXO1 in primary myoblasts and in several ARMS cell lines.

Applications

  • Application: WB

Handling

  • Format: Liquid
  • Unit size: 100 ug
  • Shipping conditions: Shipping at 4° C

References

  • Loupe et al. 2015. Oncogenesis. 4:e145. PMID: 25821947.
  • Dietz et al. 2011. Int J Biochem Cell Biol. 43(6):936-45. PMID: 21440083.